The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
暂无分享,去创建一个
Luisa M. Rodriguez | R. Heptulla | L. Bomgaars | Krishnavathana Hassan | Xiaoying Yu | Vandana S. Raman | Kimberly J. Mason | Vandana Raman
[1] J. Holst,et al. GLP‐1: physiological effects and potential therapeutic applications , 2008, Diabetes, obesity & metabolism.
[2] M. Haymond,et al. The Role of Prandial Pramlintide in the Treatment of Adolescents With Type 1 Diabetes , 2007, Pediatric Research.
[3] M. Fisher,et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) , 2007 .
[4] G. Steil,et al. Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.
[5] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.
[6] D. Drucker. Enhancing the action of incretin hormones: a new whey forward? , 2006, Endocrinology.
[7] B. Zinman,et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.
[8] M. Haymond,et al. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. , 2005, Diabetes.
[9] T. McDonald,et al. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.
[10] A. Young,et al. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.
[11] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[12] P. Zabel,et al. Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM , 1995, Diabetes.
[13] D. Rogers,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .
[14] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[15] Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial , 1988, Diabetes Care.
[16] C. Weyer,et al. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. , 2002, Diabetes technology & therapeutics.